Growth Metrics

Moderna (MRNA) Preferred Stock Liabilities (2017)

Moderna (MRNA) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $1.2 billion as the latest value for Q4 2017.

  • Quarterly Preferred Stock Liabilities changed N/A to $1.2 billion in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2017, changed N/A year-over-year, with the annual reading at $1.2 billion for FY2017, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2017 was $1.2 billion at Moderna.
  • The five-year high for Preferred Stock Liabilities was $1.2 billion in Q4 2017, with the low at $1.2 billion in Q4 2017.